Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Neurochem Int. 2016 Oct 31;107:138–147. doi: 10.1016/j.neuint.2016.10.007

Figure 2. Therapeutic time window of RTL1000 for protection from stroke in DR2-Tg mice.

Figure 2

Male DR2-Tg mice were subjected to 60-min transient MCAO and treated with 100 μg RTL1000 or 100 μl vehicle given subcutaneously (S.C.) starting at 4hr (A, B), 6hr (C) or 8hr (D) after MCAO, followed by additional injections at 24, 48 and 72 hr after MCAO. Brains were harvested 96 hrs after MCAO, brain slices were stained with TTC and infarct volumes measured and expressed as a percentage of the contralateral region. Panel A shows the four 2-mm TTC-stained coronal brain sections that cover the entire MCAO lesion in RTL1000- and vehicle-treated animals. * p<0.05 compared to vehicle group. Data are represented as mean ± SEM. Differences in infarct size were determined by 2-way ANOVA, followed by Holm-Sidak post hoc test, with the two factors being brain region and treatment group. CTX: cortex; CP: striatum; HMSPHR: hemisphere. Reprinted in part from Translational Stroke Research. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. 6(1):60–8. 2015. Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, Alkayed NJ. © Springer Science+Business Media New York 2014. With permission of Springer.